Benitec Biopharma Announces Updated Investor Webcast Information
Benitec Biopharma Inc. (NASDAQ: BNTC) has announced updated investor webcast information for their BB-301 Phase 1b/2a Clinical Study update. The webcast is scheduled for October 14th at 8:30 am EDT, replacing the previously announced conference call information from October 12th.
The live webcast will feature a presentation of interim clinical study data, including insights from management and Dr. Emily Plowman, Professor at The Ohio State University College of Medicine. Investors can access the webcast through a provided link, and a replay along with presentation slides will be available on the company's website afterward.
Benitec Biopharma is a clinical-stage biotechnology company focused on developing novel genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform.
Benitec Biopharma Inc. (NASDAQ: BNTC) ha annunciato informazioni aggiornate per il webcast per investitori riguardante l'aggiornamento dello studio clinico BB-301 Fase 1b/2a. Il webcast è programmato per il 14 ottobre alle 8:30 am EDT, sostituendo le informazioni precedentemente annunciate per la conference call del 12 ottobre.
Il webcast dal vivo presenterà i dati interim dello studio clinico, inclusi approfondimenti da parte della direzione e Dr. Emily Plowman, Professore presso il College of Medicine della Ohio State University. Gli investitori potranno accedere al webcast tramite un link fornito, e una registrazione insieme alle slide della presentazione sarà disponibile sul sito web dell'azienda successivamente.
Benitec Biopharma è una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di nuovi medicinali genetici utilizzando la propria piattaforma proprietaria di interferenza RNA DNA-diretta 'Silence and Replace' (ddRNAi).
Benitec Biopharma Inc. (NASDAQ: BNTC) ha anunciado información actualizada sobre el webcast para inversores referente a la actualización del estudio clínico BB-301 Fase 1b/2a. El webcast está programado para el 14 de octubre a las 8:30 am EDT, reemplazando la información de la llamada de conferencia previamente anunciada para el 12 de octubre.
El webcast en vivo presentará datos intermedios del estudio clínico, incluidos conocimientos de la dirección y Dr. Emily Plowman, profesora en el College of Medicine de la Universidad Estatal de Ohio. Los inversores podrán acceder al webcast a través de un enlace proporcionado, y una repetición junto con las diapositivas de la presentación estará disponible en el sitio web de la empresa posteriormente.
Benitec Biopharma es una compañía biotecnológica en fase clínica centrada en el desarrollo de nuevos medicamentos genéticos utilizando su plataforma propietaria de interferencia de ARN dirigida por ADN 'Silence and Replace' (ddRNAi).
Benitec Biopharma Inc. (NASDAQ: BNTC)는 BB-301 1b/2a 임상 연구 업데이트에 대한 투자자 웹캐스트 정보를 업데이트했다고 발표했습니다. 웹캐스트는 10월 14일 오전 8시 30분 EDT에 예정되며, 10월 12일에 발표된 컨퍼런스 콜 정보를 대체합니다.
실시간 웹캐스트에서는 임상 연구 데이터의 중간 발표와 함께 경영진 및 Emily Plowman 박사, 오하이오주립대학교 의대 교수의 통찰력이 포함됩니다. 투자자는 제공된 링크를 통해 웹캐스트에 접속할 수 있으며, 이후 회사 웹사이트에서 발표 슬라이드와 함께 다시 볼 수 있습니다.
Benitec Biopharma는 독자적인 'Silence and Replace' DNA 유도 RNA 간섭(ddRNAi) 플랫폼을 사용하여 새로운 유전자 의약품을 개발하는 임상 단계의 바이오테크 회사입니다.
Benitec Biopharma Inc. (NASDAQ: BNTC) a annoncé des informations mises à jour concernant le webcast pour investisseurs relatif à la mise à jour de l'étude clinique BB-301 Phase 1b/2a. Le webcast est prévu pour le 14 octobre à 8h30 EDT, remplaçant les informations de conférence téléphonique précédemment annoncées pour le 12 octobre.
Le webcast en direct présentera des données intermédiaires de l'étude clinique, y compris des insights de la direction et Dr. Emily Plowman, Professeur au College of Medicine de l'Université d'État de l'Ohio. Les investisseurs peuvent accéder au webcast via un lien fourni, et un replay ainsi que les diapositives de présentation seront disponibles sur le site web de l'entreprise par la suite.
Benitec Biopharma est une entreprise de biotechnologie en phase clinique qui se concentre sur le développement de nouveaux médicaments génétiques en utilisant sa plateforme propriétaire 'Silence and Replace' d'interférence ARN dirigée par ADN (ddRNAi).
Benitec Biopharma Inc. (NASDAQ: BNTC) hat aktualisierte Informationen zum Investoren-Webcast für ihre BB-301 Phase 1b/2a klinische Studienaktualisierung bekannt gegeben. Der Webcast ist für den 14. Oktober um 8:30 Uhr EDT angesetzt und ersetzt die zuvor angekündigten Konferenzanrufinformationen vom 12. Oktober.
Der Live-Webcast wird eine Präsentation der vorläufigen klinischen Studiendaten beinhalten, einschließlich Einblicke von der Geschäftsführung und Dr. Emily Plowman, Professorin am College of Medicine der Ohio State University. Investoren können über einen bereitgestellten Link auf den Webcast zugreifen, und eine Wiederholung sowie die Präsentationsfolien werden danach auf der Unternehmenswebsite verfügbar sein.
Benitec Biopharma ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger genetischer Medikamente mit seiner proprietären 'Silence and Replace' DNA-gesteuerten RNA-Interferenz (ddRNAi) Plattform konzentriert.
- Hosting an investor webcast to provide updates on the BB-301 Phase 1b/2a Clinical Study
- Inclusion of expert commentary from Dr. Emily Plowman, enhancing credibility of the presentation
- Availability of event replay and slides on the company website for investor accessibility
- None.
-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below-
-The webcast access information has been revised from the conference call information provided on October 12th-
HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday, October 12th.
Company Webcast Information:
Webcast title: Interim BB-301 Phase 1b Clinical Study Update
A live webcast of the interim clinical data presentation, including management and Emily Plowman, PhD, CCC-SLP, FASHA – Professor, Department of Otolaryngology – Head and Neck Surgery, The Ohio State University College of Medicine, will be held at 8:30AM EDT on Monday October 14th, 2024, and can be accessed by clicking on this link https://lifescievents.com/event/benitecbiopharma/.
The event replay and corresponding slides will be placed on the News & Events tab on the Investor page of the Benitec website.
About OPMD
OPMD is a rare progressive muscle-wasting disease caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene, for which there is currently no effective drug therapy. The disease is characterized by swallowing difficulties (dysphagia), limb weakness and eyelid drooping (ptosis). Dysphagia worsens over time and can lead to chronic choking, regurgitation, aspiration pneumonia, and in severe cases, death. Available clinical and surgical interventions are limited in scope and effectiveness and do not address the underlying progressive muscle weakness.
About BB-301
BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1. The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant expression while providing a functional replacement protein.
About Benitec Biopharma, Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and potentially commercialize its product candidates, the timing of completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, the intellectual property position, and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the Company’s ability to satisfy its capital needs through increasing its revenue and obtaining additional financing, given market conditions and other factors, including our capital structure; our ability to continue as a going concern; the length of time over which the Company expects its cash and cash equivalents to be sufficient to execute on its business plan; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors, LLC
(917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
When is Benitec Biopharma (BNTC) hosting its investor webcast for the BB-301 study update?
What is the purpose of Benitec Biopharma's (BNTC) upcoming webcast?
Who will be presenting during Benitec Biopharma's (BNTC) investor webcast on October 14th?